New Teva data highlights advances in multiple sclerosis treatment research

Leading Israeli drugmaker Teva Pharmaceutical Industries says that that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Dusseldorf, Germany, September 9-12, 2009. Featured presentations and abstracts will include new data on Copaxone (glatiramer acetate), a treatment for relapsing-remitting MS (RRMS), as well as on the company's compounds in advanced development.

"For nearly two decades Teva has supported the MS community and our ongoing commitment to research and development will continue to provide effective MS treatments while maintaining safety as well as contribute to a greater understanding of the disease,' said Moshe Manor, Teva's group vice president, Global Branded Products. 'Our dedication has not only brought forth the world's leading MS treatment, Copaxone, but we are looking forward to continually support the MS community through our evolving pipeline, led by oral laquinimod.'

Teva will present data on the effect of Copaxone on the Multiple Sclerosis Severity Score (MSSS) from the longest ongoing prospective study of an immunomodulatory therapy in RRMS. In addition, Teva and Active Biotech will present data on laquinimod, its investigational oral, once-daily, immunomodulating compound being developed for the treatment of RRMS. New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.